Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

• Alexandra Leary,
• Purificación Estévez-García,
• Renaud Sabatier,
• Isabelle Ray-Coquard,
• Margarita Romeo,
• Pilar Barretina-Ginesta,
• Marta Gil-Martin,
• Elena Garralda,
• Joaquim Bosch-Barrera,
• Teresa Morán,
• Paloma Martin-Martorell,
• Ernest Nadal,
• Pere Gascón,
• Jordi Rodon,
• Jose M Lizcano,
• Pau Muñoz-Guardiola,
• Gemma Fierro-Durán,
• Oriol Pedrós-Gámez,
• Héctor Pérez-Montoyo,
• Marc Yeste-Velasco,
• Marc Cortal,
• Antonio Pérez-Campos,
• Jose Alfon,
• Carles Domenech,
• Alejandro Pérez-Fidalgo,
• Ana Oaknin

Affiliations

Alexandra Leary

Medical Oncology, Institut Gustave Roussy

Purificación Estévez-García

Medical Oncology, Hospital Universitario Virgen del Rocío

Renaud Sabatier

Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes

Isabelle Ray-Coquard

Medical Oncology, Centre Léon Bérard

Margarita Romeo

Department of Medical Oncology, Department of Medicine, Institut Català d’Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona

Pilar Barretina-Ginesta

Medical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d’Oncologia (ICO), Medical School University of Girona (UdG)

Marta Gil-Martin

Medical Oncology, Catalan Institute of Oncology and IDIBELL, L’Hospitalet del Llobregat

Elena Garralda

Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO)

Joaquim Bosch-Barrera

Medical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d’Oncologia (ICO), Medical School University of Girona (UdG)

Teresa Morán

Department of Medical Oncology, Department of Medicine, Institut Català d’Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona

Paloma Martin-Martorell

Medical Oncology, INCLIVA-Hospital Clínico Universitario

Ernest Nadal

Medical Oncology, Catalan Institute of Oncology and IDIBELL, L’Hospitalet del Llobregat

Pere Gascón

Medical Oncology Service, Hospital Clínic. Universitat de Barcelona

Jordi Rodon

Early Drug Development, The University of Texas M. D. Anderson Cancer Center

Jose M Lizcano

Department of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona

Pau Muñoz-Guardiola

Department of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona

Gemma Fierro-Durán

Research and Development, Ability Pharmaceuticals

Oriol Pedrós-Gámez

Research and Development, Ability Pharmaceuticals

Héctor Pérez-Montoyo

Research and Development, Ability Pharmaceuticals

Marc Yeste-Velasco

Research and Development, Ability Pharmaceuticals

Marc Cortal

Research and Development, Ability Pharmaceuticals

Antonio Pérez-Campos

Research and Development, Ability Pharmaceuticals

Jose Alfon

Research and Development, Ability Pharmaceuticals

Carles Domenech

Research and Development, Ability Pharmaceuticals

Alejandro Pérez-Fidalgo

Medical Oncology, INCLIVA-Hospital Clínico Universitario

Ana Oaknin

Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO)